TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Trading Down 9.2 %

Shares of NASDAQ:TXMD opened at $1.14 on Wednesday. TherapeuticsMD has a 1 year low of $0.70 and a 1 year high of $2.75. The firm has a fifty day moving average price of $1.31 and a 200 day moving average price of $1.57.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.